Anemoside A3

CAS No. 129724-84-1

Anemoside A3( —— )

Catalog No. M17927 CAS No. 129724-84-1

Anemoside A3 is an attractive candidate for further development as a cognitive enhancer capable of alleviating memory dysfunctions associated with aging and neurodegenerative diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 60 In Stock
10MG 86 In Stock
25MG 141 In Stock
50MG 207 In Stock
100MG 304 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Anemoside A3
  • Note
    Research use only, not for human use.
  • Brief Description
    Anemoside A3 is an attractive candidate for further development as a cognitive enhancer capable of alleviating memory dysfunctions associated with aging and neurodegenerative diseases.
  • Description
    Anemoside A3 is an attractive candidate for further development as a cognitive enhancer capable of alleviating memory dysfunctions associated with aging and neurodegenerative diseases.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    Others
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    129724-84-1
  • Formula Weight
    750.96
  • Molecular Formula
    C41H66O12
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (66.58 mM)
  • SMILES
    [C@H]12[C@@](CC[C@]3([C@@]4(CC[C@H]5[C@]([C@H](CC[C@@]5([C@H]4CC[C@H]13)C)O[C@@H]1OC[C@@H]([C@@H]([C@H]1O[C@@H]1O[C@H]([C@@H]([C@H]([C@H]1O)O)O)C)O)O)(C)CO)C)C)(CC[C@H]2C(=C)C)C(=O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ip FC, Fu WY, Cheng EY, Tong EP, et al.Anemoside A3 Enhances Cognition through the Regulation of Synaptic Function and Neuroprotection.Neuropsychopharmacology. 2015 Jul;40(8):1877-87.
molnova catalog
related products
  • VEGFR-2-IN-9

    VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor with an IC50 of 7 nM, suitable for breast cancer research.

  • DMH4

    DMH4 is a potent and selective inhibitor of VEGFR2 with an IC50 of 0.16 μM.

  • Cediranib

    A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively.